Lyka Labs Approves Divestment Of 100% Stake In Lyka BDR

Q1 FY27 Consolidated Results YoY: Revenue at 42.3 Cr vs 33.0 Cr, up 28.1%. EBITDA at 5.0 Cr vs 4.3 Cr, up 15.0%. EBITDA Margin at 11.7% vs 13.1%, contraction of 130bps. PAT at 2.0 Cr vs 1.0 Cr, up 105.4%. Board approved divestment of its 100% stake in Lyka BDR International; sale terms, consideration and completion date remain to be finalized. The subsidiary contributed 10.6 Cr of FY26 income, equivalent to 8% of consolidated income, and had negative net worth of 4.5 Cr. Context: follows the subsidiary’s prior impairment and continuing losses.